About the Elsevier SciVal Suite
Elsevier's SciVal® suite of services supports academic and government leadership in evaluating, establishing and executing research strategies that optimize the performance of existing assets and maximize investments to enhance near and long-term productivity. SciVal tools leverage Scopus® data, Elsevier's trusted source of bibliometric data, to offer innovative yet authoritative solutions. Current suite offerings include: SciVal Spotlight, a strategic tool that generates unique institutional and country maps of existing and emerging research strengths based on an interdisciplinary perspective of current performance; SciVal Funding, an online solution that provides targeted recommendations on grants to pursue based on pre-populated research profiles and historical awards; SciVal Strata, a web-based research performance tool that offers users the flexibility to construct relevant contextual data to evaluate research teams or individual researchers, using a range of indicators based on Scopus data; SciVal Experts, a semantic technology-based application that enables researchers to identify and locate sources of expertise at an individual or departmental level within and across institutions.
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include ScienceDirect, Scopus, Reaxys, MD Consult and Mosby's Nursing Suite, which enhance the productivity of science and health professionals, and the SciVal suite and MEDai's Pinpoint Review, which help research and health care institutions deliver better outcomes more cost-effectively. A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC, a world-leading publisher and information provider, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).Media contact Iris Kisjes Elsevier +31-20-485-3072 email@example.com SOURCE Elsevier
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV